Process development: replicating the final cell therapy product
Disease-state leukopaks are effective surrogates for establishing cell therapy manufacturing parameters.
Read MoreIsolating rare cell types from peripheral blood
Leukopaks from patients provide large pools of PBMCs.
Read MoreExpanding the reach of clinical trials
Immunogenicity biomarkers in individuals previously infected with COVID-19 were used to evaluate vaccines in preclinical and clinical trials.
Read MoreLinking a drug mechanism to a human disease
A specific autoimmune indication was identified for a novel therapy using patient donor biospecimens.
Read MoreDescribing the patient experience in biomarkers
A prospective, longitudinal study using in-home collected biospecimens identified a panel of predictive biomarkers.
Read MoreBuilding Confidence for First-in-Human Trials
Confirming preclinical pharmacology in whole blood from MS patients.
Read MoreHybrid by Design: Patient Centricity in Clinical Trials
As an X-linked disorder, Duchenne’s muscular dystrophy (DMD) primarily affects males, with an incidence of one in every…
Read MoreEasing Participation Burden for Families with Crohn’s Disease
The increasing prevalence of Crohn’s disease (CD), an inflammatory bowel disease, drives increased scientific interest in understanding its…
Read MoreMulti-Collection Capabilities: Powering Microbiome Discovery in Cancer
In recent years, the dynamic interplay between the microbiota, tumor microenvironment, and the immune system has been thrust…
Read MoreScores for Stratification: Systemic Lupus Erythematosus
The broad spectrum of clinical manifestations seen in systemic lupus erythematosus (SLE) makes it challenging to characterize the…
Read More